Monogenic variants in dystonia: an exome-wide sequencing study.
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
11
03
2020
revised:
30
07
2020
accepted:
10
08
2020
entrez:
25
10
2020
pubmed:
26
10
2020
medline:
4
11
2020
Statut:
ppublish
Résumé
Dystonia is a clinically and genetically heterogeneous condition that occurs in isolation (isolated dystonia), in combination with other movement disorders (combined dystonia), or in the context of multisymptomatic phenotypes (isolated or combined dystonia with other neurological involvement). However, our understanding of its aetiology is still incomplete. We aimed to elucidate the monogenic causes for the major clinical categories of dystonia. For this exome-wide sequencing study, study participants were identified at 33 movement-disorder and neuropaediatric specialty centres in Austria, Czech Republic, France, Germany, Poland, Slovakia, and Switzerland. Each individual with dystonia was diagnosed in accordance with the dystonia consensus definition. Index cases were eligible for this study if they had no previous genetic diagnosis and no indication of an acquired cause of their illness. The second criterion was not applied to a subset of participants with a working clinical diagnosis of dystonic cerebral palsy. Genomic DNA was extracted from blood of participants and whole-exome sequenced. To find causative variants in known disorder-associated genes, all variants were filtered, and unreported variants were classified according to American College of Medical Genetics and Genomics guidelines. All considered variants were reviewed in expert round-table sessions to validate their clinical significance. Variants that survived filtering and interpretation procedures were defined as diagnostic variants. In the cases that went undiagnosed, candidate dystonia-causing genes were prioritised in a stepwise workflow. We sequenced the exomes of 764 individuals with dystonia and 346 healthy parents who were recruited between June 1, 2015, and July 31, 2019. We identified causative or probable causative variants in 135 (19%) of 728 families, involving 78 distinct monogenic disorders. We observed a larger proportion of individuals with diagnostic variants in those with dystonia (either isolated or combined) with coexisting non-movement disorder-related neurological symptoms (100 [45%] of 222; excepting cases with evidence of perinatal brain injury) than in those with combined (19 [19%] of 98) or isolated (16 [4%] of 388) dystonia. Across all categories of dystonia, 104 (65%) of the 160 detected variants affected genes which are associated with neurodevelopmental disorders. We found diagnostic variants in 11 genes not previously linked to dystonia, and propose a predictive clinical score that could guide the implementation of exome sequencing in routine diagnostics. In cases without perinatal sentinel events, genomic alterations contributed substantively to the diagnosis of dystonic cerebral palsy. In 15 families, we delineated 12 candidate genes. These include IMPDH2, encoding a key purine biosynthetic enzyme, for which robust evidence existed for its involvement in a neurodevelopmental disorder with dystonia. We identified six variants in IMPDH2, collected from four independent cohorts, that were predicted to be deleterious de-novo variants and expected to result in deregulation of purine metabolism. In this study, we have determined the role of monogenic variants across the range of dystonic disorders, providing guidance for the introduction of personalised care strategies and fostering follow-up pathophysiological explorations. Else Kröner-Fresenius-Stiftung, Technische Universität München, Helmholtz Zentrum München, Medizinische Universität Innsbruck, Charles University in Prague, Czech Ministry of Education, the Slovak Grant and Development Agency, the Slovak Research and Grant Agency.
Sections du résumé
BACKGROUND
Dystonia is a clinically and genetically heterogeneous condition that occurs in isolation (isolated dystonia), in combination with other movement disorders (combined dystonia), or in the context of multisymptomatic phenotypes (isolated or combined dystonia with other neurological involvement). However, our understanding of its aetiology is still incomplete. We aimed to elucidate the monogenic causes for the major clinical categories of dystonia.
METHODS
For this exome-wide sequencing study, study participants were identified at 33 movement-disorder and neuropaediatric specialty centres in Austria, Czech Republic, France, Germany, Poland, Slovakia, and Switzerland. Each individual with dystonia was diagnosed in accordance with the dystonia consensus definition. Index cases were eligible for this study if they had no previous genetic diagnosis and no indication of an acquired cause of their illness. The second criterion was not applied to a subset of participants with a working clinical diagnosis of dystonic cerebral palsy. Genomic DNA was extracted from blood of participants and whole-exome sequenced. To find causative variants in known disorder-associated genes, all variants were filtered, and unreported variants were classified according to American College of Medical Genetics and Genomics guidelines. All considered variants were reviewed in expert round-table sessions to validate their clinical significance. Variants that survived filtering and interpretation procedures were defined as diagnostic variants. In the cases that went undiagnosed, candidate dystonia-causing genes were prioritised in a stepwise workflow.
FINDINGS
We sequenced the exomes of 764 individuals with dystonia and 346 healthy parents who were recruited between June 1, 2015, and July 31, 2019. We identified causative or probable causative variants in 135 (19%) of 728 families, involving 78 distinct monogenic disorders. We observed a larger proportion of individuals with diagnostic variants in those with dystonia (either isolated or combined) with coexisting non-movement disorder-related neurological symptoms (100 [45%] of 222; excepting cases with evidence of perinatal brain injury) than in those with combined (19 [19%] of 98) or isolated (16 [4%] of 388) dystonia. Across all categories of dystonia, 104 (65%) of the 160 detected variants affected genes which are associated with neurodevelopmental disorders. We found diagnostic variants in 11 genes not previously linked to dystonia, and propose a predictive clinical score that could guide the implementation of exome sequencing in routine diagnostics. In cases without perinatal sentinel events, genomic alterations contributed substantively to the diagnosis of dystonic cerebral palsy. In 15 families, we delineated 12 candidate genes. These include IMPDH2, encoding a key purine biosynthetic enzyme, for which robust evidence existed for its involvement in a neurodevelopmental disorder with dystonia. We identified six variants in IMPDH2, collected from four independent cohorts, that were predicted to be deleterious de-novo variants and expected to result in deregulation of purine metabolism.
INTERPRETATION
In this study, we have determined the role of monogenic variants across the range of dystonic disorders, providing guidance for the introduction of personalised care strategies and fostering follow-up pathophysiological explorations.
FUNDING
Else Kröner-Fresenius-Stiftung, Technische Universität München, Helmholtz Zentrum München, Medizinische Universität Innsbruck, Charles University in Prague, Czech Ministry of Education, the Slovak Grant and Development Agency, the Slovak Research and Grant Agency.
Identifiants
pubmed: 33098801
pii: S1474-4422(20)30312-4
doi: 10.1016/S1474-4422(20)30312-4
pmc: PMC8246240
mid: NIHMS1708669
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
908-918Subventions
Organisme : NHGRI NIH HHS
ID : R01 HG009141
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Nat Commun. 2015 Nov 12;6:8923
pubmed: 26558346
Brain. 2006 May;129(Pt 5):1201-17
pubmed: 16549399
J Child Neurol. 2019 Jul;34(8):472-476
pubmed: 30963790
Clin Genet. 2020 Feb;97(2):305-311
pubmed: 31628766
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):774-81
pubmed: 25395479
Neurobiol Dis. 2011 May;42(2):202-9
pubmed: 20965251
Lancet Neurol. 2019 May;18(5):426
pubmed: 30981320
Curr Neurol Neurosci Rep. 2017 Oct 30;17(12):97
pubmed: 29086067
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Hum Genet. 2017 Jun;136(6):665-677
pubmed: 28349240
Mov Disord. 2013 Jun 15;28(7):889-98
pubmed: 23893445
Adv Exp Med Biol. 2010;664:541-8
pubmed: 20238057
Mov Disord. 2013 Jun 15;28(7):863-73
pubmed: 23649720
Mov Disord. 2019 May;34(5):625-636
pubmed: 30913345
Lancet Neurol. 2012 Mar;11(3):283-92
pubmed: 22261432
Parkinsonism Relat Disord. 2019 Dec;69:111-118
pubmed: 31731261
Brain. 2019 Jul 1;142(7):e31
pubmed: 31157359
Dev Biol. 2016 Jan 1;409(1):152-165
pubmed: 26546974
Mov Disord. 2017 Apr;32(4):549-559
pubmed: 27666935
Genet Med. 2019 Jul;21(7):1611-1620
pubmed: 30504930
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7
pubmed: 15608251
Ann Neurol. 2014 Oct;76(4):473-83
pubmed: 25131622
Genome Res. 2001 May;11(5):863-74
pubmed: 11337480
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nat Rev Dis Primers. 2018 Sep 20;4(1):25
pubmed: 30237473
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Mov Disord. 2013 Jun 15;28(7):990-1000
pubmed: 23893455